Genmab A/S |
Datum/Zeit | / |
Diff. / Diff.(%) | - / |
Geld | - |
Brief | - |
Eröffnung | - |
Schluss Vortag | - |
Tageshoch | - |
Tagestief | - |
Volumen [DKK] | - |
Volumen [Stück] | |
Preisfeststellungen | |
ISIN | DK0010272202 |
Wertpapier | GMAB |
Börse | OMX Nordic |
Typ | Aktie |
Andere Handelsplätze
Börse | Aktuell | Volumen | |
---|---|---|---|
Lang & Schwa.. | 286,20 | ![]() |
|
OMX Nordic | 2.130,00 | ![]() |
132.969 |
Cboe Europe .. | 2.132,00 | ![]() |
32.467 |
Turquoise | 2.131,00 | ![]() |
17.915 |
London Inter.. | 2.131,0 | ![]() |
3.018 |
Nasdaq Other.. | 342,9400 | ![]() |
212 |
Cboe Europe .. | 2.132,50 | ![]() |
80 |
Cboe Europe .. | 2.136,50 | ![]() |
69 |
München | 286,00 | ![]() |
20 |
TradeGate | 287,000 | ![]() |
12 |
Frankfurt | 285,9000 | ![]() |
11 |
Vienna Globa.. | 287,00 | ![]() |
0 |
Düsseldorf | 286,20 | ![]() |
0 |
Berlin | 288,20 | ![]() |
0 |
Stuttgart | 285,800 | ![]() |
0 |
gettex | 285,900 | ![]() |
|
Mexico | 7.638,15 | ![]() |
11.330 |
Nachrichten
- Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
09.04.2021 / 22:00 - GlobeNewswire - Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study
01.04.2021 / 12:45 - GlobeNewswire - Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents
31.03.2021 / 12:45 - GlobeNewswire - BioNTech Announces Full Year 2020 Financial Results and Corporate Update
30.03.2021 / 12:30 - GlobeNewswire - Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
30.03.2021 / 07:21 - GlobeNewswire